Thus, the polymorphism may play a role in dictating the evolution of the malignancy whereby MEN1 acts as a ‘driver’ gene and the CDKN1B polymorphism as a ‘modifier’ of tumour progression. The gene discussed is MEN1; the disease is neoplasm.